Lumito's technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Lumito AB (publ) ("Lumito" or the "Company") today announces that its joint work together with Boston Cell Standards, was featured in a scientific poster presentation at the 2026 Winter Meeting of The Pathological Society of Great Britain & Ireland, which took place 20-21 January 2026.

The poster, authored and presented by Keith Miller, focuses on recent advances in HER2 calibrators (i.e., reference material containing a precisely known amount of HER2, enabling standardisation and comparability between laboratories) as well as novel slide-based technologies for HER2 labelling, developed through collaborative efforts between the teams in the United States and in Sweden. The initiative was driven by Keith who identified the work as highly relevant to the pathology community and of significant interest to laboratories seeking to further improve their immunohistochemistry (IHC) services.

The inclusion of this work at one of the UK and Ireland's leading pathology meetings underscores the growing international interest and market pull for standardised, high-quality solutions in HER2 testing. The same can be applied to companion diagnostics such as PD-L1 and Oestrogen Receptor

> "My aim with this poster was to showcase the important and complementary work being carried out on both sides of the Atlantic. There is clear demand within the pathology community for robust IHC calibration tools and improvements in IHC labelling for critical companion diagnostics, such as those for HER2. These developments are absolutely essential, if IHC testing centres are to meet the ever-increasing standards required for patient care,"says Keith Miller, Honorary Associate Professor at the Research Department of Pathology, UCL Cancer Institute, London and honorary member of The Pathological Society of Great Britain & Ireland.

Miller, who spent four decades working in IHC, was the lead of the UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ Hybridisation. He was also founder of UCL-Advanced Diagnostics, a UK reference centre laboratory for IHC that is now under the Health Service Laboratories in London.

The poster provides an update on ongoing developments and serves to inform pathologists, laboratory managers and decision-makers about technologies that are already available, as well as innovations expected to reach the market in the near future.

The poster is available on Lumito's website, here.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Lumito's technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026